United States Patent 8,546,548 (IgG Concentration/Diafiltration with Membrane Washing and Membrane-Scale Switching): Claim Scope, Validity Risk, and Competitive Patent Landscape
Executive summary
- USP 8,546,548 claims a process for making high-concentration human IgG (final >20% w/v, optionally ~20% w/v) using ultrafiltration/diafiltration, with a specific membrane “washing” and transfer workflow: recirculate post-wash through the first ultrafiltration system using ≥2× dead volume, transfer the resulting “post-wash solution” into a second ultrafiltration system having a smaller membrane surface area (explicitly ≤1/10 in dependent claim 11), then reconcentrate and combine with the earlier concentrate.
- The claim set is narrowed by quantitative filtration parameters (initial 2–10% w/v to >20% w/v; glycine diafiltration buffer around 0.2–0.3 M at pH 4.2 ±0.1; pH of final formulation 4.0–6.0; membrane NMWCO ≤100 kDa and often ≤90 kDa or ≤60 kDa; initial concentration 5 ±1% w/v; optional “open-screen membrane”).
- The patent’s enforceability is most exposed on obviousness because the underlying unit operations (IgG UF concentration, glycine low pH diafiltration buffer exchange, membrane cleaning/washing, and multi-step UF re-concentration) are widely used in biologics manufacturing. The patent differentiator is the specific post-wash/transfer into a smaller-area membrane and recombination, but that differentiation may still read on conventional “recovery from hold-up/retentate loss” practices depending on the closest prior art.
What does US Patent 8,546,548 claim for concentrating IgG with two ultrafiltration membranes and a post-wash transfer step?
Short answer (claim 1): A method that uses two UF/diafiltration systems in sequence where the first system is used to (i) concentrate IgG, (ii) diafilter, (iii) reconcentrate to >20% w/v, then (iv) wash the first ultrafiltration membrane with ≥2× dead volume of post-wash buffer, (v) transfer that post-wash solution into a second UF system with smaller membrane surface area, (vi) reconcentrate to >20% w/v, and (vii) combine the second system’s reconcentrate with the first system’s concentrate to form a concentrated IgG composition.
Key claim elements and what they practically cover
A. Concentration and reconcentration targets
- Step (A): Concentrate IgG from 2% to 10% (w/v) to a first UF concentrate at that 2–10% range (the claim language is “concentrating … to a protein concentration of from 2% to 10% (w/v)”).
- Step (C): Concentrate the diafiltrate to >20% (w/v) by UF.
This creates a claim structure that is compatible with typical IgG feed concentration ranges and ends at a high-concentration product used for subcutaneous/IV formulations and delivery-ready concentrates.
B. Diafiltration buffer identity (independent claim vs dependent claim)
- Claim 1 requires a diafiltration step “against a diafiltration buffer” but does not fix the composition.
- Dependent claim 9 narrows the buffer to 0.2 M to 0.3 M glycine and pH 4.2 ±0.1.
That glycine/low pH exchange is a common stabilizing/virus-inactivation-adjacent framing in IgG manufacturing, so claim 9’s specificity can both narrow scope and give a clearer “obviousness” testing anchor.
C. Membrane washing with a dead-volume metric
- Step (E): wash the first ultrafiltration membrane by recirculating post-wash buffer through the first system using a volume ≥2× dead volume.
- The claim requires the wash generates a “first IgG post-wash solution,” which is then moved to the second system.
The dead-volume constraint is a meaningful quantitative limiter. It can also become a validity focal point if prior art describes similar cleaning/recovery wash volumes tied to system holdup.
D. Two-stage UF with membrane surface-area switching
- Step (F): transfer the post-wash solution into a second UF system where the surface area of the second membrane is lower than the first.
- Dependent claim 11 narrows: second membrane surface area ≤ 1/10 of the first.
This is the most “engineering-specific” part of claim 1: it implies a workflow where the process concentrates “wash fraction” using a smaller membrane area to minimize time/circulation volume, or to match concentration behavior at higher solids.
E. Combining concentrates
- Step (H): combine the third IgG concentrate (from post-wash solution reconcentration on the smaller membrane) with the earlier “second IgG concentrate.”
This is effectively a yield-recovery integration: you recover IgG that remains in system volume/near the membrane/holdup region of system 1.
Dependent claims that further fence the scope
| Dependent claim |
Added limitation |
Patent-meaning in enforceability terms |
| Claim 2 |
Initial concentration 5 ±1% (w/v) |
Narrows to a preferred feed concentration. |
| Claim 3 |
First membrane is an open-screen membrane |
Narrows to a certain membrane structure/brand class. |
| Claims 4–8 |
NMWCO ≤100 kDa and/or ≤90 kDa, and option of same NMWCO |
Narrows cut-off range; affects whether prior art with 300 kDa or 50 kDa membranes reads. |
| Claim 9 |
Diafiltration buffer: 0.2–0.3 M glycine; pH 4.2 ±0.1 |
Narrows to a common exchange buffer but with exact bounds. |
| Claim 10 |
Second concentrate ≥22% (w/v) |
Narrows the reconcentration endpoint. |
| Claim 11 |
Second membrane area ≤1/10 first |
Strong numerical limiter and likely the key “differentiator” if prior art has only “smaller membrane” generically. |
| Claim 12 |
Final concentrated IgG composition >20%, then adjust to ~20% (w/v) |
Adds a final-formulation adjustment step. |
| Claim 13 |
Final pH 4.0–6.0 |
Product specification. |
| Claim 14 |
Optional second membrane wash and admixture using second post-wash |
Extends the recovery concept to system 2. |
| Claim 15 |
IgG is human IgG |
Narrows species to human IgG (still broad across many subclasses). |
| Claim 16 |
Rewrites claim 1 with specific 5±1%, UF membranes NMWCO ≤60 kDa, glycine pH 4.2 ±0.1 diafiltration, and explicitly second membrane surface area ≤1/10; includes both post-wash steps and an additional dilution/adjustment via admixture |
A “fully specified” embodiment that will map most directly onto any matching manufacturing paper/process. |
How strong is the patent estate for USP 8,546,548 versus UF/diafiltration prior art?
Short answer: The strength depends on whether the closest prior art teaches or makes obvious the combination of (i) a specific dead-volume wash to recover IgG, (ii) transfer of that wash fraction into a second UF system, and (iii) using a much smaller membrane surface area to reconcentrate and then combine with the earlier concentrate. Without that exact integration, the claim can remain meaningfully distinguishable.
Obviousness pressure points
-
Unit operations are routine
- UF concentration of IgG, diafiltration buffer exchange, and final concentration adjustments are core steps in biologics process development.
- If prior art describes “membrane cleaning/washing” to recover protein from holdup and then reconcentrates on a second membrane, the claim can be attacked as an obvious optimization of a known process.
-
Dead-volume-based washing may be known as holdup recovery
- The claim’s “≥2× dead volume” constraint targets a specific operational parameter.
- If prior art uses system holdup volume or dead volume multiples for recovery washes, this becomes a classic “finite number of predictable options” issue.
-
Membrane area switching is an engineering choice
- Membrane surface area differences are common when moving between pilot and production systems, or when adjusting flux and residence time.
- The dependent claim’s ≤1/10 ratio is the more defensible limiter. If prior art uses a “smaller” second membrane without a numerical bound, claim 1 still covers “lower surface area,” but claim 11 would narrow.
-
Glycine/low pH diafiltration is widely disclosed
- Dependent claim 9 is likely to face obviousness if many documents disclose glycine buffers at ~pH 4.2 for IgG stabilization/viral inactivation adjacent steps.
- The novelty then shifts back to the membrane-wash/transfer/recombine architecture.
Practical implication for infringement analysis
- A manufacturer process that differs on any of these integrated features can create a non-infringement path:
- uses only a single UF system and does not transfer the post-wash solution into a second system, or
- performs washing but disposes or separately treats the wash fraction rather than reconcentrating and combining, or
- uses the second UF system with similar membrane area rather than materially smaller (especially for dependent claim 11), or
- does not use a ≥2× dead volume post-wash.
Which prior art claim elements likely map to US 8,546,548 and where are the differentiators?
Short answer: The differentiator is not “UF + diafiltration + glycine,” but the dead-volume washing to generate a wash fraction, followed by transfer to a second UF membrane system with reduced area and combination with the primary high-concentration fraction.
Element-by-element mapping framework (use for novelty charting)
| Claim element |
Prior art likelihood |
Differentiator strength |
| UF concentration of IgG from low % to concentrate |
High |
Routine. |
| Diafiltration (UFDF) of IgG |
High |
Routine; dependent claim 9 narrows buffer. |
| Concentration to >20% w/v |
Medium-High |
Common endpoint for IgG concentrates. |
| Membrane washing with post-wash solution using ≥2× dead volume |
Medium |
Quantitative wash metric can distinguish. |
| Transfer wash fraction into second UF system |
Medium |
If prior art treats wash as discard or separate pool, distinguishes. |
| Second membrane surface area lower (≤1/10 in dependent) |
Medium |
Stronger when a prior art process uses same or proportionally similar area. |
| Reconcentrate post-wash solution to >20% and combine |
Medium |
Yield-recovery recombination may be unique. |
| Glycine 0.2–0.3 M, pH 4.2 ±0.1 |
High |
Common; depends on whether the overall process integration matches. |
| Final pH 4.0–6.0 |
Medium |
Product spec can be typical. |
| Membrane NMWCO ≤100/90/60 kDa; open-screen |
Medium |
Can narrow to certain membrane selections. |
What patents protect similar IgG concentration processes in the US, and how does USP 8,546,548 compare?
Short answer: The closest patent landscape for this technology class is dominated by patents describing: (i) IgG UF/diafiltration and high-concentration formulations, (ii) buffer exchange using glycine/acetate or low pH conditions, and (iii) membrane cleaning/hold-up recovery. USP 8,546,548 attempts to claim the missing integration: quantified post-wash recovery into a second smaller-area UF step followed by pooling.
Where USP 8,546,548 likely sits relative to typical families
Without asserting specific other patent numbers (not provided in the input), USP 8,546,548 should be evaluated against three categories:
-
IgG UF concentration to high solids
- May claim general concentration ranges and membrane MWCO.
- Risk to novelty if they include post-concentration membrane washes intended for product recovery.
-
IgG diafiltration into glycine buffers at low pH
- May claim exact buffer compositions and pH.
- If those documents also include recovery washing and pooling, they may attack dependent claim 9 and independent claim 1 as obvious.
-
Membrane recovery/hold-up flushing to maximize yield
- Often framed as “recover protein retained in membrane/holdup.”
- If framed generally without two-stage UF area switching and recombination, they may not anticipate claim 1 but can drive obviousness.
What is the infringement and design-around surface for competitors?
Short answer: The most direct design-arounds are to break the claim’s integrated requirements: (i) wash volume metric, (ii) transfer to a second UF system, (iii) much smaller second membrane area, and (iv) recombination.
High-probability design-arounds
- Single-system pooling only: Keep wash solution in system 1 and do not reconcentrate in a second UF system.
- Different wash volume logic: Use a wash volume below 2× dead volume.
- No second membrane area reduction: Use a second UF system with area not materially smaller, or within a range that fails dependent claim 11.
- No pooling/recombine: Recovered wash protein is discarded, separately formulated, or removed via different unit operations.
What FDA regulatory pathway and Orange Book status apply to this method patent?
Short answer: USP 8,546,548 is a manufacturing method patent. Method patents can still be relevant to FDA regulatory exclusivity via listed patents in the Orange Book if they are listed for a specific drug product. The input provided does not include the drug name, NDA/BLA, or Orange Book listing data, so a determination cannot be made from the information provided.
Key Takeaways
- USP 8,546,548 claims an IgG manufacturing process defined less by generic UF/diafiltration and more by a quantified membrane washing and recovery integration: wash membrane 1 with ≥2× dead volume, transfer wash fraction to UF membrane 2 with smaller surface area, reconcentrate to >20% w/v, and combine with the earlier concentrate.
- Dependent claims materially narrow scope using numerical targets: initial 5 ±1%, glycine diafiltration 0.2–0.3 M at pH 4.2 ±0.1, membrane NMWCO ≤100/90/60 kDa, second membrane area ≤1/10, and final concentration/pH targets.
- Validity risk concentrates on obviousness: routine UF/diafiltration and recovery washing are common. The patent’s defendable core is the specific integrated workflow combining dead-volume wash, transfer to a smaller-area second membrane system, and reconcentrate-and-combine.
FAQs
1. What specific step in claim 1 most likely drives novelty over generic IgG UF/diafiltration?
The combination of (E) ≥2× dead-volume post-wash, (F) transferring that post-wash solution into a second UF system with reduced membrane surface area, followed by (G) reconcentrating and (H) combining with the earlier concentrate.
2. Does claim 1 require glycine in the diafiltration buffer?
No. Glycine at 0.2–0.3 M and pH 4.2 ±0.1 is in dependent claim 9.
3. What membrane cutoff values are explicitly claimed?
The claim set includes dependent limitations at ≤100 kDa, ≤90 kDa, and in the fully specified embodiment NMWCO ≤60 kDa (claim 16).
4. How can a competitor attempt to design around claim 11?
By using a second ultrafiltration membrane whose surface area is not ≤ 1/10 of the first membrane surface area, while also avoiding the overall integrated wash-transfer-recombine workflow.
5. If a process uses two UF systems, is that automatically infringing claim 1?
No. Infringement requires the functional integration of the workflow: dead-volume-based post-wash generation, transfer into the smaller-area second system, reconcentration of the post-wash solution to >20% w/v, and combining pools.
References
- United States Patent 8,546,548. (Assignee and publication details not provided in the prompt).
